Blossom keeps close track of new psychedelic research to keep you up-to-date. In cooperation with Psychedelic Alpha, we publish a monthly overview that recaps the latest research in one article. All papers that didn’t make the cut are featured in our handy link overviews.
February presented another productive month for psychedelic research. This recap of the 21 most exciting articles covers intracellular neuroplasticity, brain measures, outcomes from psychedelic-assisted therapy (PAT), psychedelics for new indications, and well-being measures.
This is all the other psychedelic research that came out in March 2023. These papers don't (yet) have their own page in our database.
This is all the other psychedelic research that came out in February 2023. These papers don't (yet) have their own page in our database.
This January, outcomes of psychedelic use were closely examined. Studies looked at how experiences are integrated, how challenging experiences lead to growth, and the relationship between psychedelic use and nature-relatedness.
In December we saw medium dose of psilocybin for depression, paradoxical wakefulness on 5-MeO-DMT, and many ketamine studies.
This is all the other psychedelic research that came out in January 2023. These papers don't (yet) have their own page in our database.
This is all the other psychedelic research that came out in December 2022. These papers don't (yet) have their own page in our database.
In November, we got results of COMPASS Pathways Phase II trial, antidepressants were found to weaken the effects of psilocybin while ketanserin has the potential to stop an LSD trip.
This is all the other psychedelic research that came out in November 2022. These papers don't (yet) have their own page in our database.
In October, natural language processing (NLP) was used to successfully predict clinical outcomes using data from a trial exploring psilocybin on treatment-resistant depression (TRD). The first real-world study assessing esketamine for TRD yielded positive results, while new evidence suggests people who microdose may build a tolerance which needs to be taken in future trials.
Research Briefings
At Blossom, we start our day by gathering the latest psychedelic research. Our inbox receives the latest from PubMed, psyarxiv, Google Scholar, and the many other sources where new research is being published.
In the monthly recap, now running for over 2 years, we bring together this deluge of information in an easy to understand format.
All papers that haven’t made the cut are still archived in our link overviews.
